Fresenius Kabi recalls Tyenne injection vial lot over glass particle contamination

• Fresenius Kabi recalled one lot of Tyenne (tocilizumab-aazg) 400 mg/20 mL vials nationwide due to glass particles.
• Recall targets lot 16UI07, NDC 65219-594-20, expiry 08/2028; shipments ran from 03/03/2026 to 03/25/2026.
• Glass particulates in injectable drugs can trigger infusion-site reactions; severe cases include vascular blockage, pulmonary embolism, organ damage, death.
• Product was distributed to US wholesalers, distributors, direct customers; facilities told to stop use, quarantine inventory, return affected units.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202608101834BIZWIRE_USPR_____20260810_BW034320) on August 10, 2026, and is solely responsible for the information contained therein.